(Bloomberg)--Bristol-Myers Squibb Co.’s immune cancer therapy won approval from U.S. regulators for a broader population of lung cancer patients, a boost for a drug that’s expected to become a blockbuster.
The decision by the Food and Drug Administration came almost three months ahead of schedule, following a trend of quicker clearances for new cancer drugs by the agency.
In March, Opdivo was approved three months ahead of plan for use in patients with advanced squamous, non-small cell lung cancer whose disease had progressed during or after trying chemotherapy.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
